Cargando…

Functional characterization of phospholipase C-γ(2) mutant protein causing both somatic ibrutinib resistance and a germline monogenic autoinflammatory disorder

Depending on its occurrence in the germline or somatic context, a single point mutation, S707Y, of phospholipase C-γ(2) (PLCγ(2)) gives rise to two distinct human disease states: acquired resistance of chronic lymphocytic leukemia cells (CLL) to inhibitors of Brutons´s tyrosine kinase (Btk) and domi...

Descripción completa

Detalles Bibliográficos
Autores principales: Walliser, Claudia, Wist, Martin, Hermkes, Elisabeth, Zhou, Yuan, Schade, Anja, Haas, Jennifer, Deinzer, Julia, Désiré, Laurent, Li, Shawn S.C., Stilgenbauer, Stephan, Milner, Joshua D., Gierschik, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188132/
https://www.ncbi.nlm.nih.gov/pubmed/30344948
http://dx.doi.org/10.18632/oncotarget.26173
_version_ 1783363163991834624
author Walliser, Claudia
Wist, Martin
Hermkes, Elisabeth
Zhou, Yuan
Schade, Anja
Haas, Jennifer
Deinzer, Julia
Désiré, Laurent
Li, Shawn S.C.
Stilgenbauer, Stephan
Milner, Joshua D.
Gierschik, Peter
author_facet Walliser, Claudia
Wist, Martin
Hermkes, Elisabeth
Zhou, Yuan
Schade, Anja
Haas, Jennifer
Deinzer, Julia
Désiré, Laurent
Li, Shawn S.C.
Stilgenbauer, Stephan
Milner, Joshua D.
Gierschik, Peter
author_sort Walliser, Claudia
collection PubMed
description Depending on its occurrence in the germline or somatic context, a single point mutation, S707Y, of phospholipase C-γ(2) (PLCγ(2)) gives rise to two distinct human disease states: acquired resistance of chronic lymphocytic leukemia cells (CLL) to inhibitors of Brutons´s tyrosine kinase (Btk) and dominantly inherited autoinflammation and PLCγ(2)-associated antibody deficiency and immune dysregulation, APLAID, respectively. The functional relationships of the PLCγ(2)S707Y mutation to other PLCG2 mutations causing (i) Btk inhibitor resistance of CLL cells and (ii) the APLAID-related human disease PLCγ(2)-associated antibody deficiency and immune dysregulation, PLAID, revealing different clinical characteristics including cold-induced urticaria, respectively, are currently incompletely understood. Here, we show that PLCγ(2)S707 point mutants displayed much higher activities at 37° C than the CLL Btk inhibitor resistance mutants R665W and L845F and the two PLAID mutants, PLCγ(2)Δ19 and PLCγ(2)Δ20-22. Combinations of CLL Btk inhibitor resistance mutations synergized to enhance PLCγ(2) activity, with distinct functional consequences for different temporal orders of the individual mutations. Enhanced activity of PLCγ(2)S707Y was not observed in a cell-free system, suggesting that PLCγ(2) activation in intact cells is dependent on regulatory rather than mutant-enzyme-inherent influences. Unlike the two PLAID mutants, PLCγ(2)S707Y was insensitive to activation by cooling and retained marked hyperresponsiveness to activated Rac upon cooling. In contrast to the PLAID mutants, which are insensitive to activation by endogenously expressed EGF receptors, the S707Y mutation markedly enhanced the stimulatory effect of EGF, explaining some of the pathophysiological discrepancies between immune cells of PLAID and APLAID patients in response to receptor-tyrosine-kinase activation.
format Online
Article
Text
id pubmed-6188132
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-61881322018-10-21 Functional characterization of phospholipase C-γ(2) mutant protein causing both somatic ibrutinib resistance and a germline monogenic autoinflammatory disorder Walliser, Claudia Wist, Martin Hermkes, Elisabeth Zhou, Yuan Schade, Anja Haas, Jennifer Deinzer, Julia Désiré, Laurent Li, Shawn S.C. Stilgenbauer, Stephan Milner, Joshua D. Gierschik, Peter Oncotarget Research Paper Depending on its occurrence in the germline or somatic context, a single point mutation, S707Y, of phospholipase C-γ(2) (PLCγ(2)) gives rise to two distinct human disease states: acquired resistance of chronic lymphocytic leukemia cells (CLL) to inhibitors of Brutons´s tyrosine kinase (Btk) and dominantly inherited autoinflammation and PLCγ(2)-associated antibody deficiency and immune dysregulation, APLAID, respectively. The functional relationships of the PLCγ(2)S707Y mutation to other PLCG2 mutations causing (i) Btk inhibitor resistance of CLL cells and (ii) the APLAID-related human disease PLCγ(2)-associated antibody deficiency and immune dysregulation, PLAID, revealing different clinical characteristics including cold-induced urticaria, respectively, are currently incompletely understood. Here, we show that PLCγ(2)S707 point mutants displayed much higher activities at 37° C than the CLL Btk inhibitor resistance mutants R665W and L845F and the two PLAID mutants, PLCγ(2)Δ19 and PLCγ(2)Δ20-22. Combinations of CLL Btk inhibitor resistance mutations synergized to enhance PLCγ(2) activity, with distinct functional consequences for different temporal orders of the individual mutations. Enhanced activity of PLCγ(2)S707Y was not observed in a cell-free system, suggesting that PLCγ(2) activation in intact cells is dependent on regulatory rather than mutant-enzyme-inherent influences. Unlike the two PLAID mutants, PLCγ(2)S707Y was insensitive to activation by cooling and retained marked hyperresponsiveness to activated Rac upon cooling. In contrast to the PLAID mutants, which are insensitive to activation by endogenously expressed EGF receptors, the S707Y mutation markedly enhanced the stimulatory effect of EGF, explaining some of the pathophysiological discrepancies between immune cells of PLAID and APLAID patients in response to receptor-tyrosine-kinase activation. Impact Journals LLC 2018-09-28 /pmc/articles/PMC6188132/ /pubmed/30344948 http://dx.doi.org/10.18632/oncotarget.26173 Text en Copyright: © 2018 Walliser et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (http://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Walliser, Claudia
Wist, Martin
Hermkes, Elisabeth
Zhou, Yuan
Schade, Anja
Haas, Jennifer
Deinzer, Julia
Désiré, Laurent
Li, Shawn S.C.
Stilgenbauer, Stephan
Milner, Joshua D.
Gierschik, Peter
Functional characterization of phospholipase C-γ(2) mutant protein causing both somatic ibrutinib resistance and a germline monogenic autoinflammatory disorder
title Functional characterization of phospholipase C-γ(2) mutant protein causing both somatic ibrutinib resistance and a germline monogenic autoinflammatory disorder
title_full Functional characterization of phospholipase C-γ(2) mutant protein causing both somatic ibrutinib resistance and a germline monogenic autoinflammatory disorder
title_fullStr Functional characterization of phospholipase C-γ(2) mutant protein causing both somatic ibrutinib resistance and a germline monogenic autoinflammatory disorder
title_full_unstemmed Functional characterization of phospholipase C-γ(2) mutant protein causing both somatic ibrutinib resistance and a germline monogenic autoinflammatory disorder
title_short Functional characterization of phospholipase C-γ(2) mutant protein causing both somatic ibrutinib resistance and a germline monogenic autoinflammatory disorder
title_sort functional characterization of phospholipase c-γ(2) mutant protein causing both somatic ibrutinib resistance and a germline monogenic autoinflammatory disorder
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188132/
https://www.ncbi.nlm.nih.gov/pubmed/30344948
http://dx.doi.org/10.18632/oncotarget.26173
work_keys_str_mv AT walliserclaudia functionalcharacterizationofphospholipasecg2mutantproteincausingbothsomaticibrutinibresistanceandagermlinemonogenicautoinflammatorydisorder
AT wistmartin functionalcharacterizationofphospholipasecg2mutantproteincausingbothsomaticibrutinibresistanceandagermlinemonogenicautoinflammatorydisorder
AT hermkeselisabeth functionalcharacterizationofphospholipasecg2mutantproteincausingbothsomaticibrutinibresistanceandagermlinemonogenicautoinflammatorydisorder
AT zhouyuan functionalcharacterizationofphospholipasecg2mutantproteincausingbothsomaticibrutinibresistanceandagermlinemonogenicautoinflammatorydisorder
AT schadeanja functionalcharacterizationofphospholipasecg2mutantproteincausingbothsomaticibrutinibresistanceandagermlinemonogenicautoinflammatorydisorder
AT haasjennifer functionalcharacterizationofphospholipasecg2mutantproteincausingbothsomaticibrutinibresistanceandagermlinemonogenicautoinflammatorydisorder
AT deinzerjulia functionalcharacterizationofphospholipasecg2mutantproteincausingbothsomaticibrutinibresistanceandagermlinemonogenicautoinflammatorydisorder
AT desirelaurent functionalcharacterizationofphospholipasecg2mutantproteincausingbothsomaticibrutinibresistanceandagermlinemonogenicautoinflammatorydisorder
AT lishawnsc functionalcharacterizationofphospholipasecg2mutantproteincausingbothsomaticibrutinibresistanceandagermlinemonogenicautoinflammatorydisorder
AT stilgenbauerstephan functionalcharacterizationofphospholipasecg2mutantproteincausingbothsomaticibrutinibresistanceandagermlinemonogenicautoinflammatorydisorder
AT milnerjoshuad functionalcharacterizationofphospholipasecg2mutantproteincausingbothsomaticibrutinibresistanceandagermlinemonogenicautoinflammatorydisorder
AT gierschikpeter functionalcharacterizationofphospholipasecg2mutantproteincausingbothsomaticibrutinibresistanceandagermlinemonogenicautoinflammatorydisorder